Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
Lu W, Lyu H, Xiao X, Bai X, Zhang M, Wang J, Pu Y, Meng J, Zhang X, Zhu H, Yuan T, Wang B, Jin X, Cao X, Wang Z, Xie T, Meng H, Stepanov AV, Gabibov AG, An Y, Sun R, Zhang Y, Maschan MA, Zhu Z, Zhang H, Zhao M. Lu W, et al. Among authors: meng j, meng h. Leukemia. 2024 Apr 17. doi: 10.1038/s41375-024-02251-5. Online ahead of print. Leukemia. 2024. PMID: 38632315 No abstract available.
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
He X, Xiao X, Li Q, Jiang Y, Cao Y, Sun R, Jin X, Yuan T, Meng J, Ma L, Lu W, Lyu C, Liu K, Zhao M. He X, et al. Among authors: meng j. Leukemia. 2019 Aug;33(8):2102-2104. doi: 10.1038/s41375-019-0437-5. Epub 2019 Mar 7. Leukemia. 2019. PMID: 30846865 Free PMC article. No abstract available.
HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, Xiao X, Jiang Y, Li Q, Zhang H, Lu W, Lyu C, Jiang Y, Meng J, Zhao M. Jin X, et al. Among authors: meng j. Leukemia. 2020 Mar;34(3):909-913. doi: 10.1038/s41375-019-0610-x. Epub 2019 Oct 18. Leukemia. 2020. PMID: 31628429 Free PMC article. No abstract available.
Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation.
Lyu H, Lu W, Yao J, Xiao X, Li Q, Wang J, Mu J, Qi Y, Zhu H, Jiang Y, Li X, Meng J, Yuan T, He X, Jiang E, Han M, Zhao M. Lyu H, et al. Among authors: meng j. Leuk Lymphoma. 2020 Apr;61(4):840-847. doi: 10.1080/10428194.2019.1695053. Epub 2019 Nov 28. Leuk Lymphoma. 2020. PMID: 31777304
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, Jiang Y, Zhang H, Li X, Jiang Y, Meng J, Yuan T, Zhu H, He X, Jin X, Sun R, Sui T, Liu K, Zhao M. Lu W, et al. Among authors: meng j. Cancer Immunol Immunother. 2021 Dec;70(12):3501-3511. doi: 10.1007/s00262-021-02941-4. Epub 2021 Apr 25. Cancer Immunol Immunother. 2021. PMID: 33899130 Free PMC article. Clinical Trial.
A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients.
Lu W, Jin X, Lyu H, Bai X, Zhu H, Li X, Xiao X, Meng J, Yuan T, Li Q, Mu J, Lyu C, Jiang Y, Wei Y, Xiong X, Zhang M, Zhao M. Lu W, et al. Among authors: meng j. Cell Transplant. 2022 Jan-Dec;31:9636897221076050. doi: 10.1177/09636897221076050. Cell Transplant. 2022. PMID: 35168385 Free PMC article.
5,751 results